Sage Journals: Discover world-class research

Abstract

Background

The glucocorticoid receptor gene (NR3C1) encodes the receptor to which cortisol and other glucocorticoids bind. Steroids in either oral, intratympanic, or intravascular forms are the treatment of choice for sudden sensorineural hearing loss (SSNHL), but the outcome varies. The outcomes of SSNHL have been investigated for related factors, including age, initial hearing loss severity and pattern, vertigo, genetic variations, and the time between onset and treatment. The objective of the present study was to analyze the association of genetic polymorphisms of NR3C1 with the outcomes of SSNHL.

Materials and methods

We conducted a comparison study of 93 cases with a poor outcome (control) and 100 cases with a good outcome (case) in SSNHL patients. Six single nucleotide polymorphisms (SNPs) were selected. The genotypes were determined using TaqMan technology.

Results

The heterozygous AT genotype of rs17100289 was associated with a poor outcome in comparison with the major homozygous AA genotype after adjustments for age and sex (OR = 0.50; 95% CI 0.26–0.95; P = 0.035) in SSNHL patients. The CT genotype of rs4912912 was also associated with a poor outcome compared with the major homozygous TT genotype after the adjustments (OR = 0.47; 95% CI 0.24–0.92; P = 0.026).

Conclusion

These results suggest that NR3C1 genetic polymorphisms may influence the outcomes of SSNHL.

Graphical Abstract

Keywords

Genetic polymorphism Outcomes Steroid receptor gene sudden sensorineural hearing loss

Introduction

Sudden sensorineural hearing loss (SSNHL) is defined as a loss of at least 30 dB in three contiguous frequencies over 3 days or less [1]. The estimated incidence is between 5 and 20 per 100,000 persons per year in the United States [1]. The incidence rates per a population of 100,000 in Taiwan are 8.85 for men and 7.79 for women [2]. The detailed etiology and pathogenesis of SSNHL are still unclear. Potential causes may include viral infection, vascular disease, intracochlear membrane rupture, autoimmunity, and genetic factors. [3]. Histopathologic studies of SSNHL revealed changes in the cochlea, including atrophy of the organ of Corti and loss of cochlear neurons, which was the main finding in viral Inflammation [4]. However, there is no consensus, and the etiology and pathogenesis of SSNHL remain controversial.

Merchant et al. [5] revealed that a final common pathway for several possible etiologies of sudden sensorineural hearing loss may be the result of pathologic activation of cellular stress pathways involving nuclear factor kappa B (NF-kB) within the cochlea. Cortisol acts in the regulation of other glucocorticoid-responsive genes and is involved in interactions between the cortisol-glucocorticoid receptor complex and other transcription factors, such as NF-kB. The cortisol-glucocorticoid receptor complex also physically interacts with NF-kB to block its transcriptional activity leading to the anti-inflammatory effect [6].

Several factors related to the outcomes of SSNHL, including age, initial hearing loss severity and pattern, vertigo, and the time between onset and treatment, have been investigated [7–9]. Steroids (glucocorticoids) in either oral, intratympanic, or intravascular forms are the treatment of choice for SSNHL patients, but the outcome varies [7, 10]. The efficacy of glucocorticoids (GCs) in alleviating inflammatory disorders results from the pleiotropic effects of the glucocorticoid receptor (GR) on multiple signaling pathways [6]. The distribution of GRs in the cochlea appears to be subsite specific. GRs are expressed at highest concentrations with in the organ of Corti, followed by the spiral ganglion neurons (SGNs), and are present in lower concentration within the stria vascularis and fibrocytes of the lateral cochlear wall [11]. In an animal study, the authors found intense nuclear immunofluorescence at basal and apical SGN regions after GC administrated either via local or systemic route, which was greater than control tissue. And the GR activation of the SGNs was equivalent in both administration regimens [12]. The above findings indicate that GCs may bind to the nuclear GRs in the inner ear to perform the anti-inflammatory effect in SSNHL.

GR is a member of the steroid hormone receptor family of proteins [13]. GR binds with high affinity to cortisol in the cell, and the cortisol-GR complex inhibits inflammation through direct and indirect genomic effects and nongenomic mechanisms[6]. GR is known as nuclear receptor subfamily 3 Group C member 1 (NR3C1). The NR3C1 gene is located on chromosome 5q31–32. Variation in the structure and the expression of the gene generates diversity in glucocorticoid signaling [14]. However, there is little published literature about the relationship between the corticosteroid receptor gene and the outcomes of SSNHL. Kitoh et al. reported a marginal correlation between the single nucleotide polymorphism (SNP) of the NR3C1 gene (rs4912910) and steroid treatment outcomes in SSNHL patients [15]. Genetic polymorphisms of the NR3C1 gene might alter the affinity of GR to corticosteroids, affect the anti-inflammatory effect, and lead to a poorer outcome in SSNHL.

There is no doubt that the evaluation of genetic polymorphisms in SSNHL is important because identifying patients with genotypes with a poor outcome may help us develop optimal treatment strategies. In the present study, we hypothesize that the SNPs of the GR gene (i.e., the NR3C1 gene) may be crucial for the outcomes of SSNHL. The goal of this study was to understand the role of NR3C1 genetic polymorphisms in the outcomes of SSNHL after steroid treatment in Taiwan.

Materials and methods

Study population

In this prospective study, we randomly recruited participants from SSNHL patients diagnosed and treated in an academic medical center (Kaohsiung Medical University Hospital). The diagnostic criteria of SSNHL were sensorineural hearing loss of at least 30 dB in 3 contiguous frequencies using a pure tone audiogram with an onset within 3 days [2]. Patients who were traditionally considered to have a better outcome were included in the present study. These better prognostic factors included age younger than 50 years, no vertigo, initial hearing loss < 90 dBHL, and less than 7 days from onset to treatment [7–9].

All the patients were hospitalized for one week. They received prednisolone orally (1 mg/kg for 2 days), which was decreased over the next 2 weeks. During hospitalization, all the patients received audiometric tests, including pure tone audiometry (PTA), auditory brainstem-evoked responses, and magnetic resonance imaging (to exclude acoustic neuroma). After discharge, the PTA changes were monitored for at least six weeks to determine the outcome of each patient.

To investigate the factors associated with the efficacy of steroid treatment for SSNHL, the patients were separated into two groups based on outcomes. The classification of good and poor outcomes was based on the recommendations of the “Clinical Practice Guideline: Sudden Hearing Loss” from the American Academy of Otolaryngology-Head and Neck Surgery (AAO-HNS) in 2012[16]. A complete recovery requires hearing return to within 10 dB HL of the unaffected ear and recovery of word recognition sore (WRS) to within 5% to 10% of the unaffected ear. Anything less than a 10 dB HL improvement should be classified as no recovery. Partial recovery defined in 2 ways (clinically meaningful recovery/ not meaningful recovery) based on whether or not the degree of initial hearing loss after the event of SSNHL rendered the ear nonserviceableb (PTA > 50 dB or WRS < 50%). The patients with “complete recovery” and “meaningful partial recovery” were classified into the good outcome (case) group. The patients with “not meaningful partial recovery” and “no recovery” were categorized into the poor outcome (control) group.

Genetic analysis

SNP selection

We selected all SNPs of NR3C1 from the released 2.0 phase II data of the HapMap Project [17] using the Tagger Pairwise method [18]. The SNPs were chosen according to the following criteria: r² was 0.8 or greater and the minor allele frequency (MAF) was more than 25% in the Han Chinese population. Six SNPs met the above criteria and were selected for genotyping: rs6877893, rs4912912, rs17100289, rs12653301, rs4912650, and rs9324924 of the NR3C1 gene.

Genotyping

Genomic DNA was extracted from peripheral blood before treatment using a standard method. Genotyping was performed using TaqMan technology (7500 Real Time PCR System, Applied Biosystems, Foster City, CA, USA), and reactions were performed in 96-well microplates in ABI 9700 thermal cyclers (Applied Biosystems, Foster City, CA, USA). Fluorescence was measured using an ABI 7500 Real-Time PCR System and analyzed with System SDS software version 1.2.3. Each subject was typed for all SNPs.

Statistical analysis

Continuous variables were analyzed using independent t-tests, and the results are presented as the means ± SD. The allele frequency was obtained using direct gene counting. The mixture Hardy–Weinberg equilibrium (mHWE) was examined in the participants[19]. The effect of the minor allele of each SNP was examined in dominant and recessive genetic models. Multivariate logistic regression analysis was performed to obtain the age- and sex-adjusted odds ratio (OR) and 95% confidence interval (95% CI) while assessing the genetic effects. All statistical operations were performed using JMP software version 13.0 (SAS Institute Inc., Cary City, NC, USA) for Windows. Two-tailed P values < 0.05 were considered significant.

Results

Participants

A total of 193 SSNHL patients were included in the present study. In the poor outcome group, there were 93 patients, including 60 (64.5%) males and 33 (35.5%) females. In the good outcome group, there were 100 patients, including 64 (64.0%) males and 36 (36.0%) females. The characteristics of SSNHL are summarized in Table 1. The mean age of the 193 participants was 38.8 ± 10.8 years. The mean ages were 38.8 ± 10.9 years and 38.9 ± 10.7 years in the poor outcome and good outcome groups, respectively. The male to female ratio was 1.8:1 in the 193 SSNHL patients. The age and sex characteristics were not significantly different between the poor and good outcome groups.

Table 1

Demographics of subjects in the poor and good outcomes groups

Outcomes	Poor (n = 93)	Good (n = 100)	P value
Age (mean ± SD, y/o)	38.8 ± 10.9	38.9 ± 10.7	0.9304¹
Sex (n, %)
Male	60(64.5)	64(64.0)	0.9404²
Female	33(35.5)	36(36.0)
Hearing loss type
High	18(19.4)	10(10.0)	0.1556²
Flat	64(68.8)	74(74.0)
Total	11(11.8)	16(16.0)
PTA (mean ± SD, dB)
Pre-treatment	68.83 ± 24.03	62.71 ± 21.00	0.0605¹
Post-treatment	56.08 ± 20.56	28.43 ± 16.84	< 0.0001^*1
Change in hearing level	6.63 ± 12.43	40.40 ± 18.94	< 0.0001^*1
SRT (mean ± SD, dB)
Pre-treatment	64.38 ± 25.52	56.75 ± 29.31	0.1174¹
Post-treatment	52.61 ± 26.28	37.15 ± 27.44	0.0013^*1
SDS (mean ± SD, %)
Pre-treatment	55.39 ± 36.17	62.65 ± 39.00	0.2732¹
Post-treatment	63.22 ± 37.46	82.52 ± 30.03	0.0013^*1

¹ Independent t-test

² χ² test

*P < 0.05

Pure-tone average (PTA) by average of pure-tone hearing threshold by air conduction at 0.5, 1, 2, and 3 kHz

Abbreviations: pure-tone average (PTA), speech discrimination score (SDS), speech reception threshold (SRT)

Genetic analysis

There were significant differences in the distributions of the genotypes of NR3C1 rs17100289 (χ² test, P = 0.003) and rs4912912 (χ² test, P = 0.030) between the poor and good outcome groups. The AT genotype of rs17100289 was associated with a poor outcome in comparison with the AA genotype after adjustments for age and sex (OR = 0.50; 95% CI 0.26–0.95; P = 0.035). The CT genotype of rs4912912 was also associated with a poor outcome compared with the TT genotype after adjustments (OR = 0.47; 95% CI 0.24–0.92; P = 0.026). However, the genotypic and allelic distributions showed no significant difference between the groups for the other SNPs (rs12653301, rs4912650, rs6877893, and rs9324924). The results of allele and genotype analyses are presented in Table 2.

Table 2

Associations of six single nucleotide polymorphisms (SNPs) of the NR3C1 gene with sudden sensorineural hearing loss (SSNHL)

SNP	Overall, n (%)		P value¹	Adjusted OR (95% CI)²	P value³
SNP	Poor	Good	P value¹	Adjusted OR (95% CI)²	P value³
rs12653301
Genotypes
GG	31 (33)	34 (34)	0.967	1.00⁴
AG	42 (45)	46 (46)		1.00 (0.52–1.9)	0.999
AA	20 (22)	20 (20)		1.91(0.41–2.01)	0.822
Alleles
G	104 (56)	114 (57)	0.830	1.00⁴
A	82 (44)	86 (43)		0.958 (0.64–1.43)	0.834
rs17100289
Genotypes
AA	28 (30)	37 (37)	0.003*	1.00⁴
AT	54 (58)	36 (36)		0.50 (0.26–0.95)	0.035*
TT	11 (12)	27 (27)		1.84 (0.79–4.46)	0.159
Alleles
A	110 (59)	110 (55)	0.412	1.00⁴
T	76 (41)	90 (45)		1.18 (0.79–1.78)	0.416
rs4912650
Genotypes
TT	36 (39)	40 (40)	0.917	1.00⁴
GT	42 (45)	46 (46)		0.99 (0.53–1.83)	0.963
GG	15 (16)	14 (14)		0.84 (0.35–1.98)	0.689
Alleles
T	114 (61)	126 (63)	0.729	1.00⁴
G	72 (39)	74 (37)		0.93 (0.62–1.40)	0.728
rs4912912
Genotypes
TT	24 (26)	36 (38)	0.030*	1.00⁴
CT	53 (57)	38 (38)		0.47 (0.24–0.92)	0.026*
CC	16 (17)	26 (26)		1.09 (0.49–2.47)	0.836
Alleles
T	101 (54)	110 (55)	0.890	1.00⁴
C	85 (46)	90 (45)		0.97 (0.65–1.45)	0.891
rs6877893
Genotypes
AA	54 (58)	57 (57)	0.988	1.00⁴
AG	31 (33)	34 (34)		1.04 (0.56–1.92)	0.903
GG	8 (9)	9 (9)		1.07 (0.38–3.03)	0.904
Alleles
A	139 (75)	148 (74)	0.869	1.00⁴
G	47 (25)	52 (26)		1.04 (0.66–1.64)	0.871
rs9324924
Genotypes
GG	32 (34)	32 (32)	0.931	1.00⁴
GT	49 (53)	54 (54)		1.11 (0.59–2.07)	0.754
TT	12 (13)	14 (14)		1.17 (0.47–2.98)	0.732
Alleles
G	113 (61)	118 (59)	0.726	1.00⁴
T	73 (39)	82 (41)		1.08 (0.72–1.62)	0.717

¹χ² test

²Adjusted for age and sex

³Logistic regression

⁴Reference group

*P < 0.05

The hereditary models (dominant and recessive) were analyzed in each SNP. A significant result was observed from the recessive model for NR3C1 rs17100289, which yielded an adjusted OR of 2.76 (95% CI 1.31–6.17, P = 0.007) for the TT genotype compared with the AA + AT genotypes after adjustment for age and sex. Participants who carried the TT homozygote of NR3C1 rs17100289 were associated with a better outcome of SSNHL. However, no significant association of the hereditary model with the outcomes of SSNHL was found in the other five SNPs (rs12653301, rs4912650, rs4912912, rs6877893, and rs9324924). The hereditary models are summarized in Table 3.

Table 3

Dominant and recessive hereditary models

SNP	Overall, n (%)		P value¹	Adjusted OR (95% CI)²	P value³
SNP	Poor	Good	P value¹	Adjusted OR (95% CI)²	P value³
rs12653301
Genotypes
GG	31 (33)	34 (34)	0.922	1.00⁴
AG + AA	62 (67)	66 (66)		0.97 (0.53–1.77)	0.927
GG + AG	73 (78)	80 (80)	0.797	1.00⁴
AA	20 (22)	20 (20)		0.91 (0.45–1.84)	0.799
rs17100289
Genotypes
AA	28 (30)	37 (37)	0.311	1.00⁴
AT + TT	65 (70)	63 (63)		0.73 (0.39–1.33)	0.301
AA + AT	82 (88)	73 (73)	0.008*	1.00⁴
TT	11 (12)	27 (27)		2.76 (1.31–6.17)	0.007*
rs4912650
Genotypes
TT	36 (39)	40 (40)	0.855	1.00⁴
GT + GG	57 (61)	60 (60)		0.95 (0.53–1.69)	0.854
TT + GT	78 (84)	86 (86)	0.679	1.00⁴
GG	15 (16)	14 (14)		0.85 (0.381.87)	0.678
rs4912912
Genotypes
TT	24 (26)	36 (36)	0.126	1.00⁴
CT + CC	69 (74)	64 (64)		0.62 (0.33–1.14)	0.124
TT + CT	77 (83)	74 (74)	0.134	1.00⁴
CC	16 (17)	26 (26)		1.70 (0.85–3.49)	0.134
rs6877893
Genotypes
AA	54 (58)	57 (57)	0.881	1.00⁴
AG + GG	39 (42)	43 (43)		1.04 (0.59–1.85)	0.882
AA + AG	85 (91)	91 (91)	0.922	1.00⁴
GG	8 (9)	9 (9)		1.05 (0.38–2.92)	0.923
rs9324924
Genotypes
GG	32 (34)	32 (31)	0.723	1.00⁴
GT + TT	61 (66)	68 (68)		1.12 (0.61–2.05)	0.715
GG + GT	81 (87)	86 (86)	0.823	1.00⁴
TT	12 (13)	14 (14)		1.10 (0.48–2.59)	0.816

¹χ² test

²Adjusted for age and sex

³Logistic regression

⁴Reference group

*P < 0.05

Discussion

This study investigated the relationship between six SNPs of the NR3C1 gene and the outcomes of SSNHL in a Taiwanese population and found that NR3C1 has an evident genetic effect on the outcomes of SSNHL. The significant result stemmed from the rs17100289 polymorphisms of the NR3C1 gene, highlighting the role this rare TT genotype of rs17100289 has in the protection against SSNHL in Taiwan. Patients with the CT genotype of rs4912912 had a higher risk of a poor outcome than those with the major homozygous genotype TT. We found no significant difference between the poor and good prognostic groups at SNPs rs12653301, rs4912650, rs6877893, and rs9324924 in SSNHL. This investigation is the first report of the potential contribution specifically by NR3C1 genetic variants to the outcomes of SSNHL.

Furthermore, our recessive models yielded a significant adjusted OR of 2.76 (P = 0.007) for TT versus AA + AT of rs17100289 after adjustment for age and sex. This result revealed a tendency for TT to have a better prognostic effect on SSNHL than the AA + AT genotype. The TT allele of rs17100289 seems to be a protective genotype with a recessive effect on SSNHL in Taiwan. The insignificant result of the minor homozygous TT compared with the major homozygous AA genotypes of rs17100289 in the genotype analysis might be caused by the small number of TT carriers in this study population. SNP rs17100289 has not been previously reported to be associated with hearing impairment.

The outcomes of SSNHL remain a controversial issue and is usually assessed by analyses of factors that correlate with hearing improvement. The results were inconsistent due to the various therapeutic strategies and multiple outcome definitions for recovery. The outcome of SSNHL has been investigated for its relation to several factors, including age, initial hearing loss severity and pattern, vertigo, underlying diseases, and the duration between onset and treatment [9]. Steroids have been used to treat sudden sensorineural hearing loss for a long time, but the results varied even in patients with the same condition. We have different steroid receptor genotypes and phenotypes; perhaps this is the reason why we have varied results even with the same treatment. However, there are few studies about the relationship between the genetic variations of steroid receptors and the outcomes of SSNHL.

The GR gene (NR3C1) has a three-domain structure: an amino-terminal transactivation domain, a DNA-binding domain, and carboxy-terminal ligand binding [6, 20]. The carboxy-terminal ligand binding domain contains specific steroid and heat shock protein binding sites [6, 21]. Previous research revealed that heat shock protein 70 gene polymorphisms influence the risk of SSNHL in Taiwan [22]. During the unliganded form of the GR, it is located in the cytoplasm in a large complex form of protein. After binding to cortisol, it dissociates, and a conformational change occurs. Then, the GR translocates to the nucleus, where it acts as a transcription factor to regulate the transcription of the GR gene by several mechanisms [23].

GR gene polymorphism is a possible factor that influences GC sensitivity. A number of polymorphisms in the GR gene are known. A few of these polymorphisms are functionally relevant. ER22/23EK (rs6189 and rs6190), N363S (rs6195), and BclI (rs41423247) are the three most commonly investigated GR gene polymorphisms [20]. The ER22/23EK polymorphism and relative GC resistance have shown diminished transactivational activity. The N363S polymorphism was reported to be associated with enhanced sensitivity to GCs. The BclI polymorphism is also associated with increased GC sensitivity [20].

The strength of this study is that the results give us a light to the precision medicine in the treatment of SSNHL. Based on the genetic differences, we might tailor the treatment strategy for each SSNHL patient to get the best outcome in the future. There are several limitations in the present study. The major limitation of this study is that it only included subjects in Eastern Asia. Further studies among different ethnic groups are needed to further generalize our results. The second limitation is the small sample size in the present study. The results of the present study would be more evident if the sample size enlarged. Another limitation is that only the patients traditionally considered to have better outcomes were included in the present study. To include all patients without predicting the outcomes might make the results more convincing. In addition, further functional analyses of the SNPs in the NR3C1 gene and their relationship with SSNHL are warranted.

Conclusions

The results of this study support the finding that genetic polymorphisms of the NR3C1 gene are associated with the outcomes of SSNHL after steroid treatment in a Taiwanese population.

Footnotes

Acknowledgements

We thank the Ministry of Science and Technology for supporting this study with grant MOST 108-2314-B-037-087, Kaohsiung Medical University Hospital for grant KMUH108-8R49, and Kaohsiung Municipal Siaogang Hospital for grant Kmhk-110-06.

Author contributions

Draft of the manuscript (CCY, CNC), specimen and data analysis (LKH, YHL), data collection (TSY, WLF), review of the manuscript (HKY, CNC), supervision of the project and final approval of the manuscript (CNC). The author(s) read and approved the final manuscript.

Funding

Not applicable.

Availability of data and materials

Not applicable.

Declarations

Publisher's Note

Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.

References

Byl

Sudden hearing loss: eight years’ experience and suggested prognostic table

Laryngoscope 1984 94 5 Pt 1 647 661 6325838

Lin

Chao

Sudden sensorineural hearing loss: evidence from Taiwan

Audiol Neurootol 2006 11 3 151 156 10.1159/000091198 16449805

Schreiber

Agrup

Haskard

Luxon

Sudden sensorineural hearing loss

Lancet 2010 375 9721 1203 1211 10.1016/S0140-6736(09)62071-7 20362815

Koc

Sanisoglu

Sudden sensorineural hearing loss: literature survey on recent studies

J Otolaryngol 2003 32 5 308 313 10.2310/7070.2003.11288 14974861

Merchant

Adams

Nadol

Pathology and pathophysiology of idiopathic sudden sensorineural hearing loss

Otol Neurotol 2005 26 2 151 160 10.1097/00129492-200503000-00004 15793397

Rhen

Cidlowski

Antiinflammatory action of glucocorticoids–new mechanisms for old drugs

N Engl J Med 2005 353 16 1711 1723 1:CAS:528:DC%2BD2MXhtFansrrI 10.1056/NEJMra050541 16236742

Chang

Kuo

Audiometric patterns and prognosis in sudden sensorineural hearing loss in southern Taiwan

Otolaryngol Head Neck Surg 2005 133 6 916 922 10.1016/j.otohns.2005.09.018 16360514

Singh

Kumar Irugu

Sudden sensorineural hearing loss–a contemporary review of management issues

J Otol 2020 15 2 67 73 10.1016/j.joto.2019.07.001 32440269

Chien

Tai

Wang

Hsi

Chang

Metabolic syndrome increases the risk of sudden sensorineural hearing loss in Taiwan: a case-control study

Otolaryngol Head Neck Surg 2015 153 1 105 111 10.1177/0194599815575713 25805640

10.

Chandrasekhar

Tsai Do

Schwartz SR Bontempo

Faucett

Finestone

Clinical practice guideline: sudden hearing loss (update)

Otolaryngol Head Neck Surg 2019 161 1_suppl S1 S45 31369359

11.

Zuo

Curtis

Yao

ten Cate

Bagger-Sjoback

Hultcrantz

Glucocorticoid receptor expression in the postnatal rat cochlea

Hear Res 1995 87 1–2 220 227 1:CAS:528:DyaK2MXpslSkt7o%3D 10.1016/0378-5955(95)00092-I 8567439

12.

Creber

Eastwood

Hampson

Tan

O'Leary

A comparison of cochlear distribution and glucocorticoid receptor activation in local and systemic dexamethasone drug delivery regimes

Hear Res 2018 368 75 85 1:CAS:528:DC%2BC1cXntVKltrY%3D 10.1016/j.heares.2018.03.018 29622283

13.

Laudet

Hanni

Coll

Catzeflis

Stehelin

Evolution of the nuclear receptor gene superfamily

EMBO J 1992 11 3 1003 1013 1:CAS:528:DyaK38Xks1Gitrc%3D 10.1002/j.1460-2075.1992.tb05139.x 1312460 556541

14.

Cidlowski

The origin and functions of multiple human glucocorticoid receptor isoforms

Ann N Y Acad Sci 2004 1024 102 123 1:CAS:528:DC%2BD2cXmtl2lt7k%3D 10.1196/annals.1321.008 15265776

15.

Kitoh

Nishio

Usami

Prognostic impact of gene polymorphisms in patients with idiopathic sudden sensorineural hearing loss

Acta Otolaryngol 2017 137 sup565 S24 S29 1:CAS:528:DC%2BC2sXlvVeqtb8%3D 10.1080/00016489.2017.1296971 28366034

16.

Stachler

Chandrasekhar

Archer

Rosenfeld

Schwartz SR Barrs

Clinical practice guideline: sudden hearing loss

Otolaryngol Head Neck Surg 2012 146 3 Suppl S1 35 22383545

17.

International HapMap C

A haplotype map of the human genome

Nature 2005 437 7063 1299 1320 10.1038/nature04226

18.

Barrett

Fry

Maller

Daly

Haploview: analysis and visualization of LD and haplotype maps

Bioinformatics 2005 21 2 263 265 1:CAS:528:DC%2BD2MXkt1WitQ%3D%3D 10.1093/bioinformatics/bth457 15297300

19.

Wang

Shete

Using both cases and controls for testing hardy-weinberg proportions in a genetic association study

Hum Hered 2010 69 3 212 218 10.1159/000289597 20203526 2918648

20.

Chen

Glucocorticoid receptor gene polymorphisms and glucocorticoid resistance in inflammatory bowel disease: a meta-analysis

Dig Dis Sci 2012 57 12 3065 3075 1:CAS:528:DC%2BC38Xhslaqt7nN 10.1007/s10620-012-2293-2 22752665

21.

Encio

Detera-Wadleigh

The genomic structure of the human glucocorticoid receptor

J Biol Chem 1991 266 11 7182 7188 1:CAS:528:DyaK3MXkt1ent7k%3D 10.1016/S0021-9258(20)89627-6 1707881

22.

Chien

Chang

Tai

Wang

Heat shock protein 70 gene polymorphisms in sudden sensorineural hearing loss

Audiol Neurootol 2012 17 6 381 385 1:CAS:528:DC%2BC38XhsVOntrrE 10.1159/000341815 22922572

23.

Schaaf

Cidlowski

Molecular determinants of glucocorticoid receptor mobility in living cells: the importance of ligand affinity

Mol Cell Biol 2003 23 6 1922 1934 1:CAS:528:DC%2BD3sXhvF2isLw%3D 10.1128/MCB.23.6.1922-1934.2003 12612067 149474

Glucocorticoid receptor ( NR3C1 ) genetic polymorphisms and the outcomes of sudden sensorineural hearing loss

Abstract

Background

Materials and methods

Results

Conclusion

Graphical Abstract

Keywords

Introduction

Materials and methods

Study population

Genetic analysis

SNP selection

Genotyping

Statistical analysis

Results

Participants

Genetic analysis

Discussion

Conclusions

Footnotes

Acknowledgements

Author contributions

Funding

Availability of data and materials

Declarations

References